Dual or single antiplatelet therapy after transcatheter aortic valve implantation? A systematic review and meta-analysis

Current Pharmaceutical Design

Volumn 22, Issue 29, 2016, Pages 4596-4603

  Vavuranakis, Manolis ^a   Siasos, Gerasimos ^a,b   Zografos, Theodoros ^a   Oikonomou, Evangelos ^a   Vrachatis, Dimitris ^a   Kalogeras, Konstantinos ^a   Papaioannou, Theodoros ^a   Kolokathis, Michail Aggelos ^a   Moldovan, Carmen ^a   Tousoulis, Dimitrios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acetylsalicylic acid; Clopidogrel; Dual antiplatelet therapy; Single antiplatelet therapy; Stroke; Transcatheter aortic valve implantation

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; TICLOPIDINE; ANTITHROMBOCYTIC AGENT;

BLEEDING; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL OUTCOME; COMPARATIVE STUDY; DATA BASE; DRUG EFFICACY; DRUG SAFETY; DUAL ANTIPLATELET THERAPY; FOLLOW UP; HEART INFARCTION; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT INDICATION; AORTIC VALVE STENOSIS;

AORTIC VALVE STENOSIS; HUMANS; PLATELET AGGREGATION INHIBITORS; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 84989244118     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160601110716     Document Type: Review

References (20)

1. Vavuranakis M, Vrachatis DA, Tousoulis D. Editorial: Bioengineering, clinical and therapeutical trends in transcatheter aortic valve implantation. Curr Pharm Des 2016; 22 (13): 1851-2.
2. Joint Task Force on the Management of Valvular Heart Disease of the European Society of ESC, European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J 2012; 33: 2451-96.
3. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2438-88.
4. Vavuranakis M, Vrachatis DA, Siasos G, et al. Managing complications in transcatheter aortic valve implantation. Hellenic J Cardiol 2015; 56 (Suppl A): 20-30.
5. Astarci P, Glineur D, Kefer J, et al. Magnetic resonance imaging evaluation of cerebral embolization during percutaneous aortic valve implantation: comparison of transfemoral and trans-apical approaches using Edwards Sapiens valve. Eur J Cardiothorac Surg 2011; 40: 475-9.
6. Kahlert P, Al-Rashid F, Dottger P, et al. Cerebral embolization during transcatheter aortic valve implantation: a transcranial Doppler study. Circulation 2012; 126: 1245-55.
7. Hamm CW, Arsalan M, Mack MJ. The future of transcatheter aortic valve implantation. Eur Heart J 2016; 37: 803-10.
8. Vavuranakis M, Kalogeras K, Vrachatis D, et al. Antithrombotic therapy in patients undergoing TAVI with concurrent atrial fibrillation. One center experience. J Thromb Thromb 2015; 40: 193-7.
9. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
10. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
11. Wells G, Shea B, O’connell D et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Otawa: OHRI, undated. Available at: www.ohri.ca [accessed 18 February 2013] 2000.
12. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002; 21: 1539-58.
13. Ussia GP, Scarabelli M, Mule M, et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2011; 108: 1772-6.
14. Poliacikova P, Cockburn J, de Belder A, Trivedi U, Hildick-Smith D. Antiplatelet and antithrombotic treatment after transcatheter aortic valve implantation-comparison of regimes. J Invasive Cardiol 2013; 25: 544-8.
15. Stabile E, Pucciarelli A, Cota L et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol 2014; 174: 624-7.
16. Durand E, Blanchard D, Chassaing S, et al. Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation. Am J Cardiol 2014; 113: 355-60.
17. Leetmaa T, Hansson NC, Leipsic J, et al. Early aortic transcatheter heart valve thrombosis: diagnostic value of contrast-enhanced multidetector computed tomography. Circ Cardiovasc Interv 2015; 8.
18. Pache G, Blanke P, Zeh W, Jander N. Cusp thrombosis after transcatheter aortic valve replacement detected by computed tomography and echocardiography. Eur Heart J 2013; 34: 3546.
19. Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 2015; 373: 2015-24.
20. Leon MB, Smith CR, Mack MJ et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; 374: 1609-20.